SG Americas Securities LLC Sells 21,842 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)

SG Americas Securities LLC decreased its stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 62.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,316 shares of the company’s stock after selling 21,842 shares during the quarter. SG Americas Securities LLC’s holdings in Allogene Therapeutics were worth $31,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its position in shares of Allogene Therapeutics by 76.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,177,619 shares of the company’s stock worth $18,675,000 after purchasing an additional 1,806,147 shares during the period. Affinity Asset Advisors LLC bought a new stake in Allogene Therapeutics during the fourth quarter valued at about $1,284,000. Caxton Associates LP lifted its position in shares of Allogene Therapeutics by 61.4% in the fourth quarter. Caxton Associates LP now owns 775,093 shares of the company’s stock valued at $2,488,000 after acquiring an additional 294,989 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new position in shares of Allogene Therapeutics in the first quarter valued at about $1,280,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Allogene Therapeutics by 20.2% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 221,094 shares of the company’s stock worth $736,000 after purchasing an additional 37,131 shares in the last quarter. 83.63% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Franz B. Humer sold 11,200 shares of Allogene Therapeutics stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $2.34, for a total transaction of $26,208.00. Following the completion of the transaction, the director now directly owns 255,253 shares of the company’s stock, valued at approximately $597,292.02. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 24.30% of the company’s stock.

Allogene Therapeutics Stock Down 4.3 %

Shares of ALLO opened at $2.68 on Wednesday. The business has a fifty day moving average of $2.59 and a 200 day moving average of $3.29. The company has a market cap of $560.12 million, a PE ratio of -1.50 and a beta of 0.85. Allogene Therapeutics, Inc. has a 52-week low of $2.01 and a 52-week high of $5.78.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Piper Sandler began coverage on Allogene Therapeutics in a research note on Friday, May 31st. They issued an “overweight” rating and a $11.00 price target for the company. HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Allogene Therapeutics in a research report on Thursday, August 15th. Canaccord Genuity Group decreased their target price on Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, August 8th. Truist Financial reissued a “buy” rating and set a $14.00 price target (down from $17.00) on shares of Allogene Therapeutics in a research note on Friday, August 9th. Finally, Oppenheimer assumed coverage on Allogene Therapeutics in a report on Thursday, August 8th. They set an “outperform” rating and a $11.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $9.96.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).